The Norwegian NBSS‐SF: Psychometric Properties in People With Multiple Sclerosis Treated With Natalizumab.
Saved in:
| Title: | The Norwegian NBSS‐SF: Psychometric Properties in People With Multiple Sclerosis Treated With Natalizumab. |
|---|---|
| Authors: | Myklebust, Harald (AUTHOR), Grønnestad, Erik (AUTHOR), Peel, Geoffrey (AUTHOR), Flemmen, Heidi Øyen (AUTHOR), Brekke, Kamilla (AUTHOR), Broch, Line (AUTHOR), Brunborg, Cathrine (AUTHOR), Celius, Elisabeth Gulowsen (AUTHOR), Simonsen, Cecilia Smith (AUTHOR), Fee, Dominic B. (AUTHOR) |
| Source: | Acta Neurologica Scandinavica. 7/16/2026, Vol. 2026, p1-8. 8p. |
| Subjects: | Natalizumab, Psychometrics, Quality of life, Neurogenic bladder, Multiple sclerosis, Questionnaires, Patient reported outcome measures |
| Abstract: | Introduction: Neurogenic lower urinary tract dysfunction (NLUTD) is common in neurological disease. Patient reported outcome measures (PROMs) can be useful for evaluating NLUTD and are recommended by guidelines. The Neurogenic Bladder Symptom Score–Short form (NBSS‐SF) is a 10‐item questionnaire that measures symptom burden and bladder‐related quality of life due to NLUTD. The aim of this study is to translate and validate the Norwegian version of the NBSS‐SF. Methods: The translation of the NBSS‐SF was done in accordance with international guidelines for cross‐cultural adaptation of questionnaires. Ten people with multiple sclerosis (pwMS) pilot‐tested the pre‐final version and the final version was made. We assessed the psychometric properties of the Norwegian NBSS‐SF in pwMS treated with natalizumab (NTZ). They completed the Norwegian NBSS‐SF and International Prostate Symptom Score (IPSS) at baseline and repeated the NBSS‐SF at second visit. Patient data was gathered from health records. Results: A total of 69 pwMS were recruited. Mean age was 46.7 years (SD 11.6), median disease duration of 10 years, and median Expanded Disability Status Scale score (EDSS) of 2.0 (range 0–8). Median NBSS‐SF‐score was 4 (range 1–19). There was good correlation (Spearman's rho = 0.51, p < 0.001) between NBSS‐SF and IPSS. NBSS‐SF‐score correlated with EDSS (Spearman's rho = 0.46). Patients treated for NLUTD had higher scores (p < 0.001). The Norwegian NBSS‐SF has good internal consistency (Cronbach's alpha = 0.88) and test–retest reliability (intraclass correlation coefficient = 0.88). Conclusion: The Norwegian NBSS‐SF proved valid and reliable for measuring symptoms of NLUTD in a cohort of pwMS treated with NTZ. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Introduction: Neurogenic lower urinary tract dysfunction (NLUTD) is common in neurological disease. Patient reported outcome measures (PROMs) can be useful for evaluating NLUTD and are recommended by guidelines. The Neurogenic Bladder Symptom Score–Short form (NBSS‐SF) is a 10‐item questionnaire that measures symptom burden and bladder‐related quality of life due to NLUTD. The aim of this study is to translate and validate the Norwegian version of the NBSS‐SF. Methods: The translation of the NBSS‐SF was done in accordance with international guidelines for cross‐cultural adaptation of questionnaires. Ten people with multiple sclerosis (pwMS) pilot‐tested the pre‐final version and the final version was made. We assessed the psychometric properties of the Norwegian NBSS‐SF in pwMS treated with natalizumab (NTZ). They completed the Norwegian NBSS‐SF and International Prostate Symptom Score (IPSS) at baseline and repeated the NBSS‐SF at second visit. Patient data was gathered from health records. Results: A total of 69 pwMS were recruited. Mean age was 46.7 years (SD 11.6), median disease duration of 10 years, and median Expanded Disability Status Scale score (EDSS) of 2.0 (range 0–8). Median NBSS‐SF‐score was 4 (range 1–19). There was good correlation (Spearman's rho = 0.51, p < 0.001) between NBSS‐SF and IPSS. NBSS‐SF‐score correlated with EDSS (Spearman's rho = 0.46). Patients treated for NLUTD had higher scores (p < 0.001). The Norwegian NBSS‐SF has good internal consistency (Cronbach's alpha = 0.88) and test–retest reliability (intraclass correlation coefficient = 0.88). Conclusion: The Norwegian NBSS‐SF proved valid and reliable for measuring symptoms of NLUTD in a cohort of pwMS treated with NTZ. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00016314 |
| DOI: | 10.1155/ane/7868813 |
